Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI stock opened at $1.50 on Friday. The company’s fifty day simple moving average is $1.95 and its two-hundred day simple moving average is $2.40. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.89. The stock has a market capitalization of $8.58 million, a price-to-earnings ratio of -0.31 and a beta of 0.26.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.